Physician profile
Madison Baker
NPI 1043974074
$4,288.75
in general payments reported to CMS, 2019-2025
21 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.01 · 2023: $45.33 · 2024: $1,954 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.80 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $945.13 | 2023-2025 | |
| Incyte Corporation | $533.81 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $343.73 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $314.79 | 2024-2025 | Tremfya |
| Amgen INC. | $314.26 | 2024-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $308.30 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $274.89 | 2024-2025 | Aklief, Nemluvio |
| Ucb, INC. | $253.33 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $167.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $160.55 | 2024-2025 | |
| Leo Pharma INC. | $159.54 | 2024-2025 | Adbry |
| Organon LLC | $102.34 | 2025 | Vtama |
| Genzyme Corporation | $77.76 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $53.89 | 2024-2025 | Dupixent |
| Almirall LLC | $53.71 | 2024-2025 | Klisyri, Seysara |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $52.01 | 2022 | |
| Journey Medical Corporation | $42.53 | 2025 | |
| Pfizer INC. | $37.71 | 2023-2024 | |
| Biofrontera INC. | $31.55 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.83 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $30.42 | 2024-2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.